High-risk mucosal types of human papillomavirus (HPV) cause anogenital and oropharyngeal cancers, whereas cutaneous types (e.g. HPV8 and 77) are suspected to be involved in non-melanoma skin cancer. The antibody response to HPVs is a key determinant of protective immunity, but not all infected individuals seroconvert. Genetic variability of the host may have large impact on seroconversion. A previous genome-wide association study (GWAS) has identified a susceptibility locus (rs41270488) for HPV8 seropositivity within the major histocompatibility complex (MHC) region. To further study this locus, we imputed alleles at classical leukocyte antigen (HLA) loci using HLA*IMP:02 with a reference panel from the HapMap Project and the 1958 Birth Cohort, and conducted an integrated analysis among 4811 central European subjects to assess the contribution of classical HLA alleles and gene copy number variation (CNV) at the hypervariable DRB locus within the MHC region to HPV seropositivity at both the individual HPV type level and the phylogenetic species level. Our study provides evidence that the association noted between rs41270488 and HPV8 seropositivity is driven by two independent variants, namely DQB1*0301 [odds ratio (OR) = 1.51, 95% confidence interval (CI) = 1.36-1.68, P = 1.0 × 10 −14 ] and DRB1*1101 (OR = 1.89, 95%CI = 1.57-2.28, P = 1.5 × 10 −11 ) within the HLA class II region. Additionally, we identified two correlated alleles DRB1*0701 (OR = 1.67, 95%CI = 1.41-1.98, P = 2.6 × 10 −9
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Introduction
The human papillomavirus (HPV) family comprises over 150 types that are grouped in different genera according to their DNA sequence homology (1) . All HPVs infect cells in the basal layer of stratified epithelia at a variety of anatomical sites, e.g. mucosa of the genital tract and skin (2) and thus can be broadly subdivided into mucosal and cutaneous types on the basis of their tissue tropism. Although the majority of HPV types are associated with benign wart-like lesions, certain mucosal HPVs of the genus alpha (α), referred to as high-risk (HR) mucosal HPV types (e.g. HPV16 and 18), are causally involved in cervical, other anogenital and oropharyngeal cancers (3) (4) (5) . In addition, several lines of evidence indicate that the HPV types of the genus beta (β) (e.g. HPV 5, 8 and 38) are associated with the development of psoriasis and non-melanoma skin cancer (NMSC), although the causal nature of such associations has been disputed (6) (7) (8) . The cutaneous HPV type 77 that belongs to genus α has been detected in NMSC of renal transplant recipients (9) (10) (11) . Despite HPV's ability to evade host defense, a successful immune response to HPV infections is established in most cases. This seems to be characterized by cell-mediated immunity that is associated with the generation of serum neutralizing antibodies (12) . Such antibody responses are generated in most, but not all, infected individuals (13) . They are directed against conformational epitope(s) on the major capsid protein L1 displayed on the outer surface of the intact virus particle and is HPV typespecific (12) . Antibody-mediated humoral immunity clears free virus particles from body fluids and can prevent viral reinfection (12, 13) . Serum neutralizing antibody levels following natural HPV infections, even at peak titers, are low (14) . This is probably due to the exclusively intraepithelial infectious cycle, as well as the production of virus particles in the superficial layer of the epithelium, distant from antigen-presenting cells (APCs) and patrolling macrophages (12) . Possibly, a large infection may produce more viral protein that may more effectively induce an antibody response (13) . It is also expected that seroconversions should occur in response to infections sufficiently persistent to be exposed to the immune system (13) . Therefore, HPV seropositivity may reflect a combination of cumulative exposure to HPV and subsequent capability of the host to mount an effective antibody response.
Genetic variability of the host may have impact on the outcome of an HPV infection, especially genetic factors that control the immune response (15) . The major histocompatibility complex (MHC) region is the most important region in the vertebrate genome with respect to infection, and is crucial in innate and adaptive immunity, where leukocyte antigen (HLA) genes and many other immune-related genes are located (16) . In particular, HLA molecules are responsible for the presentation of foreign antigens to the immune system (17) , and they may play a central role in the immune recognition and subsequent serological response. Classical HLA alleles, defined by genetic variation within the peptide-binding site of HLA genes, are believed to influence the ability to bind and present different peptide antigens (18) . Variation at classical HLA alleles has been implicated in susceptibility to a wide range of infections (18) . In addition, there is a hypervariable DRB locus located in the MHC class II region displaying gene copy number variation (CNV) between the HLA-DRB9 pseudogene and HLA-DRB1 (19) .
We have previously performed a genome-wide association study (GWAS) of seroreactivity to 13 HPV types within a central European population and identified a signal (rs41270488 or rs114427648) for HPV8 seropositivity within the MHC class II region [odds ratio (OR) = 1.59, 95% confidence interval (CI) = 1.40-1.82 for minor allele T, P = 5.5 × 10
−12
]. This finding was further replicated in another independent series (20) . However, given the complex linkage disequilibrium (LD) pattern in the MHC region as well as lack of data on classical HLA alleles and the CNV at DRB locus, it is not clear whether the association with rs41270488 is driven by the neighboring classical HLA alleles or CNV. It is also unknown whether any classical HLA allele or CNV within the MHC region contribute to seropositivity to other HPV types. Detailed studies of the MHC region have been hampered by the lack of methods for high throughput genotyping. Both direct high-resolution HLA genotyping and next-generation sequencing (NGS) typing do not easily scale for large cohorts. Recently, a method that allows the imputation of alleles at key classical HLA loci based on the MHC single-nucleotide polymorphism (SNP) data has become available for analysis of large-scale data sets, with accuracy that exceeds 90% at the 4-digit level (21) . Using existing genotype data from the previous GWAS of HPV seropositivity, we have performed an integrated analysis among 4811 central European subjects to assess the contribution of classical HLA alleles and CNV(s) at the hypervariable DRB locus within the MHC region to HPV seroreactivity at both the individual HPV type level and the phylogenetic species level. data available on HPV types (22) , as described in the Materials and Methods section. Following rigorous quality control (QC) steps, genome-wide SNP data were available for 4811 subjects (1286 lung cancer patients, 679 head and neck cancer patients, 811 kidney cancer patients and 2035 cancer-free subjects). L1 seropositivity for 13 HPV types had seroprevalence above 5% (α mucosal: HPV 6, 11, 16, 18, 31, 35 and 45; α cutaneous: HPV77; β cutaneous: HPV8, 38 and 49; γ cutaneous: HPV4; and μ cutaneous: HPV1). The highest seroprevalence was observed for β cutaneous HPV8 (28.04%), followed by α mucosal HPV6 (24.78%) and γ cutaneous HPV4 (24.03%) (Supplementary Material, Table S1 ). Detailed information for these 13 HPV types with the corresponding case (seropositive) and control (seronegative) counts is shown in Supplementary Material, Table S1 . There are more than one HPV type for phylogenetic species alpha-7 (HPV 18 and HPV 45), alpha-9 (HPV 16, HPV 31 and HPV 35) and alpha-10 (HPV 6 and HPV 10), while there is only one HPV type for other species in our study.
Imputation of classical HLA alleles at the 4-digit level was successfully performed at three class I loci (HLA-A, HLA-B and HLA-C) and four class II loci (HLA-DRB1, HLA-DQA1, HLA-DQB1 and HLA-DPB1) with HLA*IMP:02 (21) using a reference panel from the HapMap Project (23, 24) and the 1958 Birth Cohort (25) . As shown in Figure 1 , the gap in the MHC class II region, which is underrepresented in SNP genotyping, corresponds to the hypervariable DRB locus with CNV(s) between the HLA-DRB9 pseudogene (telomeric) and HLA-DRB1 (centromeric), where HLA class II haplotypes carry one or no additional functional HLA-DRB gene (HLA-DRB3, HLA-DRB4 or HLA-DRB5) and one, two or no additional copies of HLA-DRB pseudogene (HLA-DRB2, HLA-DRB6, HLA-DRB7 or HLA-DRB8) (Supplementary Material, Fig. S1 ) (19) . Imputation was also performed for classical HLA alleles at the additional functional genes of HLA-DRB3, HLA-DRB4 and HLA-DRB5. In total, 129 classical HLA alleles were observed in the CE study, the information of which is shown in Supplementary Material, Table S2 . Statistical analysis was performed among 4811 subjects for association between seropositivity of 13 HPV types with seroprevalence above 5% and 3 phylogenetic species (alpha-9, alpha-7 and alpha-10) and 1092 genotyped and 28 189 imputed SNPs as well as 129 imputed classical HLA alleles and 3 types of gene CNV(s) (HLA-DRB3, HLA-DRB4 or HLA-DRB5). The association results of the classical HLA alleles and gene CNV(s) across HPV types and phylogenetic species are shown in Supplementary Material, Table S3 . Given the strong LD between the variants in the MHC region, a significance threshold of P = 1.0 × 10 −6 was used.
Four HLA class II alleles showed evidence of association with HPV8 seropositivity at the P = 1.0 × 10 ) and DRB1*1101 (OR = 1.89, 95%CI = 1.57-2.28, P = 1.5 × 10 −11 ) ( Table 1) (Fig. 1A) . All of these alleles confer increased probability of antibody response against HPV8. Of the gene CNV(s) at the hypervariable DRB locus, the haplotype carrying an additional HLA-DRB3 was significantly associated with HPV8 seropositivity (OR = 1.27, 95%CI = 1.16-1.39, P = 7.0 × 10 −7 ).
The LD pattern between rs41270488 and the above HLA alleles is shown in Supplementary Material, Table S4 . To evaluate the independence of associations, we conducted stepwise logistic regression analysis. As shown in Table 2 , when conditioning on DQB1*0301, residual association was still detected at DRB1*1101, rs41270488, DQA1*0505 and DRB3*0200 but not at HLA-DRB3, with the most significant signal occurring at DRB1*1101 (OR = 1.55, 95%CI = 1.57-2.28, P = 1.0 × 10 −4 in the conditional analysis compared with OR = 1.89, 95%CI = 1.57-2.28, P = 1.5 × 10 −11 in the unconditional analysis). Further conditioning on DRB1*1101 left little evidence for residual association at rs41270488 [OR = 1.22, 95%CI = 0.96-1.55, P = 0.10), DQA1*0505 (OR = 1.40, 95%CI = 0.94-2.09, P = 0.10) and DRB3*0200 (OR = 1.10, 95%CI = 0.93-1.29, P = 0.27]. Collectively, these data provide evidence that the association we noted with rs41270488 is better explained by two independently acting classical HLA alleles for HPV8 seropositivity, defined by DQB1*0301 and DRB1*1101.
In addition, we found that DRB1*0701 and DQA1*0201 were significantly associated with HPV77 seropositivity (OR = 1.67, 95%CI = 1.41-1.98, P = 2.6 × 10 −9 and OR = 1.63, 95%CI = 1.38-1.93, P = 1.7 × 10 −8 , respectively) ( Table 3) , even though no single SNPs showed evidence of association (Fig. 1B) . These two alleles are nearly perfectly correlated with each other (D' = 1.0, r 2 = 0.96 in cancer-free subjects) and are known to occur on the same class II haplotype. No other HPV types or phylogenetic species showed statistically significant association with classical HLA alleles or CNV(s) at the DRB locus.
To validate the imputation results generated by HLA*IMP:02, the HLA alleles that were found to be significantly associated with seropositivity to HPV8 (DQB1*0301 and DRB1*1101) and HPV77 (DRB1*0701 and DQA1*0201) were also imputed with SNP2HLA using another reference panel from the Type 1 diabetes Genetics Consortium (T1DGC) (26) . As shown in Table 4 , comparable allele frequencies and association results for these HLA alleles were observed using SNP2HLA, with higher concordance observed for those with higher imputation quality, as measured Subjects that have detectable antibody to L1 of HPV8 in the serum who carry the specified HLA alleles with each genotype having a posterior probability over 0. 7. b Subjects that do not have detectable antibody to L1 of HPV8 in the serum who carry the specified HLA alleles with each genotype having a posterior probability over 0.7. Derived from unconditional logistic regression assuming a log-additive model with adjustment for age, sex, country and cancer type (control, lung cancer, kidney cancer and head and neck cancer). by Rsq, a measure of imputation quality generated by SNP2HLA, which estimates the squared correlation between imputed and true genotypes.
Discussion
In the present study, we have systematically examined the relationship between classical HLA alleles and CNV(s) at the hypervariable DRB locus within the MHC and HPV L1 seropositivity at both the individual HPV type level and the phylogenetic species level. The large data set and dense set of informative markers in our study have allowed us to detect independent effects among SNPs (both genotyped and imputed), classical HLA alleles and the CNV(s) at the hypervariable DRB locus within the MHC region. Through imputation by HLA*IMP:02 using a reference panel from the HapMap Project (23, 24) and the 1958 Birth Cohort (25), our study provides evidence that the association of rs41270488 with HPV8 seropositivity noted earlier (20) , is driven by two independently acting HLA class II alleles, defined by the DQB1*0301 and DRB1*1101 alleles. We also identified DRB1*0701 and DQA1*0201, which are nearly perfectly correlated with each other, to be associated with HPV77 seropositivity, a finding that was not detected using traditional SNP tests of association. This illustrates the power of HLA imputation for identifying new variants associated with HPV seropositivity. Comparable results were observed through imputation using SNP2HLA with another reference panel from the T1DGC. The function of the HLAs is to bind peptide fragments that are produced as a result of intracellular protein degradation. HLA then displays these fragments on the cell surface where peptides are recognized by the T cells of the host. There is now convincing evidence that different HLA alleles have been associated with susceptibility or resistance to certain infections. For example, specific class I alleles have been associated with human immunodeficiency virus (HIV) progression; B27 and B57 are associated with a good prognosis, whereas B35 is associated with a poorer one. The class II allele DRB1*1302 has shown confirmed association with spontaneous clearance of the hepatitis B virus, whereas DRB1*1101 confers protection against the infection of hepatitis C virus (18) , which was found to be associated with higher antibody reactivity to HPV77 in our study.
It is worth noting that all the associations observed in the present study are with HLA class II alleles but not with class I alleles. Class I HLA molecules are expressed by nucleated cells and present endogeneous antigens to cytotoxic CD8 + T cells, which kill the presenting cells. Class II HLA molecules are expressed on APCs (e.g. dendritic cells and macrophages) and present exogenous antigens to CD4 + T cells. CD4 + T cell activation results in the secretion of a variety of small proteins, or cytokines, that help and regulate other cells (12) . One major subset of CD4 + T cells is known as Th2 cells, which help antigen-primed B lymphocytes differentiate into plasma cells and secrete antibodies, the effector molecules of humoral response (12) . Therefore, HLA class II molecules may play a more important role in the antibody immune response against HPV infection compared with HLA class I molecules. As the interaction between the HLA class II molecule-peptide complex and the T-cell receptor is an essential step in CD4 + T-cell activation and effective humoral response, it is biologically plausible that HLA class II molecules encoded by these alleles may be more efficient in binding and presenting HPV antigens to the immune system, thereby eliciting a more efficient humoral immune response. However, it is unknown whether these classical HLA alleles are the pathogenic variant or other functional variant(s) in LD with them could be responsible. Further functional studies would help to provide insight into it.
Both of HPV8 and 77 are the cutaneous types that have been implicated in the development of NMSC. The E7 oncogene of HPV 8 has been shown to be able to transform rodent cells together with an activated Harvey rat sarcoma virus oncogene 1 (H-ras) gene and transgenic mice expressing the entire early region of HPV8 spontaneously developed multifocal skin tumors (6,7). On the other hand, the E6 oncogene of HPV77 can promote degradation of the pro-apoptotic protein BCL2-antagonist/killer 1 (Bak) and inhibit effectively UVB-induced apoptosis (11) . NMSC is the most common cancer among Caucasians. It outnumbers the total of all other cancers and has shown an increasing incidence for many years (6) . There is also a high incidence of NMSC following immunosuppressive therapy, which indicates the presence of an immune surveillance mechanism directed against viral or other foreign antigens in these cancers (28) . Given the possible role of cutaneous HPV in the etiology of NMSC, further studies are needed to examine whether the HLA variants associated with seropositivity to HPV8 and 77 affect the development of NMSC.
A limitation should be noted in the present study. Except for HPV8 and 77, we did not find evidence for that genetic variants within the MHC region contribute to the seropositivity of any other HPV type. As shown in Supplementary Material, Table S3 , suggestive associations were also observed between DQB1*0301 and higher antibody reactivity to HPV6 (OR = 1.17, 95%CI = 1.05- Subjects that have antibody to L1 of HPV77 in the serum who carry the specified HLA alleles with each genotype having a posterior probability over 0. 7. c Subjects that do not have antibody to L1 of HPV77 in the serum who carry the specified HLA alleles with each genotype having a posterior probability over 0.7. d Derived from unconditional logistic regression assuming the log-additive model with adjustment for age, sex, country and cancer type (control, lung cancer, kidney cancer and head and neck cancer).
Human Molecular Genetics, 2015, Vol. 24, No. 9 | 2685 power to detect associations of smaller magnitude for some HPV types or variants associated with HPV types with more modest seroprevalence. Larger studies with longitudinal design are needed to elucidate the genetic basis of the serological response for less frequent, particular HR mucosal HPVs. In summary, our study provides for the first time an investigation of the contribution of classical HLA alleles and the CNV(s) at the hypervariable DRB locus to HPV seropositivity at both the individual HPV type level and the phylogenetic species level within the MHC region. We have identified two independent HLA alleles, namely DQB1*0301 and DRB1*1101, that are associated with HPV8 seropositivity. We also found DRB1*0701 and/or DQA1*0201 to be associated with HPV77 seropositivity. This study provides evidence for an important role of HLA class II alleles in antibody response to HPV infections.
Materials and Methods

Study population
The CE study is a large multi-center case-control study of lung, head and neck and kidney cancer, conducted from 1998 to 2002 in six central European countries including Czech Republic, Hungary, Poland, Romania, Russia and Slovakia. Briefly, for cancer subjects, only patients newly diagnosed with histopathologically confirmed cancer were consecutively recruited. Blood samples were collected before radiotherapy and chemotherapy. Informed consent was obtained from all subjects and this study was approved by an Ethical Committee. Details on study designs and subjects recruitment have been described previously (22) . Genotying was performed on DNA samples of 1413 lung cancer cases, 742 head and neck cancer cases, 853 kidney cancer cases and 2191 cancer-free subjects using the Illumina Sentrix HumanHap300 BeadChip at the Centre National de Genotypage (CNG Paris, France) as described previously (22) . The details of QC steps have been described elsewhere (20) . Briefly, after stringent QC, data from 4811 subjects (1286 lung cancer cases, 679 head and neck cancer cases, 811 kidney cancer cases and 2035 cancer-free controls) were available for 316 015 SNPs with an overall call rate of 98.94%.
Detection of HPV serology
Serum samples from study participants were analyzed for antibodies to the HPV major capsid protein L1 (α mucosal: 6, 11, 16, 18, 31, 33, 35, 45, 52, 58; α cutaneous: 77; beta cutaneous: 8, 38 and 49; γ cutaneous: 4; and μ cutaneous: 1) at the German Cancer Research Center, Heidelberg, Germany. The multiplex serology method was applied based on a glutathione S-transferase capture (GST) enzyme linked immunosorbent assay (ELISA) in combination with fluorescent bead technology, as described previously (20, 29, 30) . More information on QC and data processing has been described elsewhere (31) .
Median R-phycoerythrin fluorescence intensity (MFI) values were dichotomized as antibody positive or negative. Seropositivity cut-offs for mucosal HPV L1 were determined using serum samples of 371 female, HPV DNA negative, self-reported virgins from a cross-sectional study among Korean students, as reported previously (32) . For assays of antibodies to the cutaneous types the definition of a mostly uninfected and thus mostly seronegative group is not possible. All antigens were identically constructed L1 fusion proteins expressed in the same bacterial expression system. The full-length L1 fusion protein density on the beads for different HPV types was very similar, since MFI values obtained after staining of the carboxy (C)-terminal tag OR, odds ratio; CI, confidence interval; P-het, P for heterogeneity.
a Imputation was performed by HLA*IMP:02 using HapMap Project (24, 25) and the 1958 Birth Cohort (26) as reference panel. Downstream analysis was restricted to subjects who carry the specified HLA alleles with each genotype having a posterior probability over 0.7.
b Imputation was performed by SNP2HLA using the Type 1 diabetes Genetics Consortium (T1DGC) (27) as reference panel. Rsq, a measure of imputation quality generated by SNP2HLA, which estimates the squared correlation between imputed and true genotypes.
h Heterogeneity in effect between the imputation by HLA*IMP:02 and SNP2HLA was evaluated using Cochran's Q-test statistic.
epitope with a monoclonal antibody varied less than 2-fold. Thus, given the similar properties of the antigens the use of a uniform cut-off appears justified. To avoid false-positivity by low-level cross-reactivity and to increase type specificity of the seroprevalence values, a uniform cut-off of 200 MFI well above background levels was chosen for cutaneous HPV L1 antibodies, as described previously (31) . A bridging panel of approximately 200 sera tested in these previous studies was re-tested side-byside with the CE serum samples, allowing normalization of the present data to the predefined cut-off values.
Statistical analysis for genotyped SNPs
For single SNP analysis, we considered the MHC to be defined by a 4.5-Mb region bordered by the Ring finger protein (RFP) and motilin (MLN) genes (rs209130 at 28 867 800 bp and rs1547668 at 33 775 446 bp, respectively) at the telomeric and centromeric ends of 6p21, respectively, which include 1092 genotyped SNPs in the CE study. All positions are with respect to build 104.0 of the Single Nucleotide Polymorphism database (dbSNP) and GRCh37.p10/ hg19 assembly of the Human Genome. The association between each SNP and HPV seropositivity at both the individual HPV type level and the phylogenetic species level was estimated by the OR per allele and 95% CI using multivariate unconditional logistic regression assuming a log-additive model with adjustment for age, sex, country and cancer type (control, lung cancer, head and neck cancer and kidney cancer) when appropriate. The potential for population stratification not accounted for by adjustment for country was also investigated by principal components analysis (PCA) undertaken with the EIGENSTRAT package (33) using 12 898 markers in low LD (34) . None of the principal components from PCA was statistically significantly associated with serological status of any HPV type (All P > 0.05) hence not included in the final model.
Imputation of SNPs within MHC and statistical analysis
As described previously (20) , genotypes for genetic variants in the MHC region not genotyped on the Illumina HumanHap300 BeadChip, but identified by the 1000 Genomes Project, were imputed using the program MACH (http://www.sph.umich.edu/csg/ abecasis/MACH/index.html, last accessed date on 10 October 2013) with phased haplotypes in 283 European subjects from the August 2010 release of the 1000 Genomes Project data as scaffold (35). For the imputed SNPs, unconditional logistic regression using posterior genotype probabilities (allele dosages) from MACH were carried out using ProbABEL (36) with adjustment for age, sex, country of origin and cancer type (control, lung cancer, head and neck cancer and kidney cancer) when appropriate. In total, 28 189 imputed SNPs with Rsq above 0.6 within the MHC region were analyzed for association with HPV seropositivity at both the individual HPV type level and the phylogenetic species level. LD statistics (D' and r 2 ) were calculated using Haploview (37) .
Imputation of classical HLA alleles and statistical analysis
For the HLA imputation, we made use of genome-wide SNP data for an extended region in 6p21 bounded by rs1165196 and rs2772372 (25 813 150 and 33 427 350 bp, respectively). With a reference database of SNP haplotypes carrying known HLA alleles from the HapMap Project (23, 24) and the 1958 Birth Cohort (25), we imputed HLA genotypes at the 4-digit level for all the subjects in the CE study using HLA*IMP:02 (21). Imputation was performed for HLA-A (n = 2474 reference samples), HLA-B (n = 3090), HLA-C (n = 2022), HLA-DQA1 (n = 175), HLA-DQB1 (n = 2629), HLA-DRB1 (n = 2665), HLA-DPB1 (n = 74), HLA-DRB3 (n = 282), HLA-DRB4 (n = 282) and HLA-DRB5 (n = 282). For each person and locus, the imputation methodology of HLA*IMP:02 returns probabilities associated with the sample having each genotype; these probabilities have been shown to be reasonably well calibrated (21) . Imputation accuracy was assessed through a crossvalidation analysis of the training data. Training was performed on two-thirds of the reference panel and tested on the remaining third at the SNPs chosen for imputation in the current study. Thresholding calls at a posterior probability of 0.7 provided accuracy of between 0.96 (HLA-DRB1) and 0.99 (HLA-DQA1, HLA-DRB4 and HLA-DRB5). To ensure the accuracy of prediction, we restricted our case-control analysis to the subjects who carry the specified HLA alleles with each genotype having a posterior probability over 0.7. Relaxing the posterior probability criterion made no substantial difference to the study findings (data not shown).
The association between each HLA allele and HPV seropositivity was estimated by OR and 95% CI per allele using unconditional logistic regression assuming a log-additive model with adjustment for age, sex, country and cancer type (control, lung cancer, head and neck cancer and kidney cancer) when appropriate. To validate the imputation results, HLA alleles that were found to be significantly associated with seropositivity to any HPV types were also imputed by SNP2HLA using the T1DGC as the reference panel which contains 5225 unrelated individuals (10 450 haplotypes) (26) . Unconditional logistic regression using posterior genotype probabilities (allele dosages) for each HLA allele from SNP2HLA were carried out using PLINK (38) with adjustment for age, sex, country and cancer type (control, lung cancer, head and neck cancer and kidney cancer) when appropriate. Unless specified, all analyses were conducted using SAS 9.3 software. All statistical tests were two-sided.
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